Mizuho analyst Anthony Petrone raised the firm’s price target on Edwards Lifesciences (EW) to $100 from $90 and keeps an Outperform rating on the shares. The company reported a strong performances across its portfolio in Q3, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target raised to $95 from $90 at Piper Sandler
- Edwards Lifesciences price target raised to $96 from $95 at Citi
- Edwards Lifesciences price target raised to $99 from $95 at Barclays
- Edwards Lifesciences Reports Strong Q3 2025 Growth
- Closing Bell Movers: Amazon soars to all-time highs on earnings